Press Releases | Eurobio Scientific

Eurobio scientific

> 2021
> 2020
> 2019

2022

October 11, 2022

H1 2022 Results: continued growth of non-COVID activity
October 3, 2022

Eurobio Scientific finalises the acquisition of GenDx, international HLA diagnostics specialist
August 17, 2022

Eurobio Scientific signs an agreement to acquire GenDx, international HLA diagnostics specialist
July 25, 2022

First half turnover of €83.6 million maintained at a high level
June 20, 2022

Launch of 2 new proprietary tests : new variants of SARS-CoV-2, and Monkeypox
June 13, 2022

Eurobio Scientific expands into Benelux by acquiring the diagnostic company Biomedical Diagnostics NV
May 18, 2022

Closing of the Strategic Partnership with NEXTSTAGE AM
April 26, 2022

Eurobio Scientific partners with Dr. Nino Guy Cassuto for the development of a new PCR test for male fertility
April 14, 2022

CE mark for Eurobio Scientific’s new proprietary test for the detection of Omicron BA.x, BA.2 and Delta variants of SARS-CoV-2
April 6, 2022

Maintaining high level results in 2021
March 10, 2022

New proprietary test for the detection of Omicron BA.x, BA.2 and Delta variants of SARS-CoV-2
February 7, 2022

Strategic partnership with NextStage AM
January 24, 2022

2021 TURNOVER : Exceptional level of €184.1million
January 11, 2022

Eurobio Scientific launches the exclusive distribution of the first saliva self-test for HIV testing in France

2021

December 13, 2021

Eurobio Scientific obtains CE marking for its proprietary test for Covid-19 screening and detection of the Omicron and Delta variants
November 30, 2021

Omicron variant : Eurobio Scientific launches the first PCR test allowing simultaneous SARS-CoV-2 virus screening and detection of the Delta and Omicron variants in a single reaction
November 23, 2021

Eurobio Scientific makes a minority investment in Usense
October 12, 2021

2021 Half-year earnings : EBITDA up +110% to €42.5m
October 6, 2021

Eurobio Scientific receives a $430,000 milestone payment from Allergan
July 26, 2021

First half turnover reaches €95.7 million, a 54% increase
May 26, 2021

Eurobio Scientific launches a new proprietary test for simultaneous detection of the SARS-CoV-2 virus and characterization of its new mutations
April 29, 2021

Exceptional 2020 results
March 9, 2021

EUROBIO Scientific extends its family of proprietary PCR tests to allow the identification of SARS-CoV-2 variants
January 25, 2021

Exceptional 2020 turnover of € 189 million (+220%)
January 18, 2021

Eurobio Scientific expands its range of COVID-19 tests with an antigenic rapid test

2020

October 15, 2020

2020 half-year results : EBITDA at €20.3 M
Septembre 22, 2020

Eurobio Scientific launches a first rapid diagnostic test for the detection of the SARS CoV-2 virus antigen
September 15, 2020

Eurobio Scientific announces the CE marking of its COVID EBX FluCoSyn™ PCR test
July 21, 2020

Very strong growth of business during the first half of 2020
July 15, 2020

Eurobio Scientific expands into Switzerland, Germany, Austria and Benelux with the acquisition of TECOmedical AG
June 9, 2020

CNR validation of two COVID-19 serology tests
May 13, 2020

Eurobio Scientific and the Hospices Civils de Lyon join forces to develop a bank of anti-SARS CoV-2 antibodies
May 11, 2020

Eurobio Scientific's proprietary PCR test confirmed as part of the fight against COVID-19
May 5, 2020

Eurobio Scientific and NG Biotech enter into a marketing agreement for COVID-19 serology rapid tests
April 14, 2020

Strong growth of 2019 annual results
March 31, 2020

Eurobio Scientific launches MagLumi COVID-19 automated test from its partner SNIBE for COVID-19 serology
March 25, 2020

Eurobio Scientific gets CE marking for its proprietary COVID-19 test
January 27, 2020

Eurobio Scientific anounced full-year revenues up 17% to €59.1M

2019

November 4, 2019

Eurobio Scientific enters into a strategic agreement for the development of proprietary products in molecular biology
October 15, 2019

Strong Earnings Growth for the First Half of 2019
October 1, 2019

Eurobio Scientific joins the Enternext PEA PME 150 index
July 23, 2019

First Semester 2019 : strong growth of sales
June 12, 2019

Eurobio Scientific and Vivo Medical Group enter into exclusive negociations for the acquisition of two companies in the United Kingdom
April 17, 2019

Eurobio Scientific - 2018 annual results
January 29, 2019

Eurobio Scientific reaches the €50M sales mark in 2018
January 08, 2019

Eurobio Scientific announces its financial communication calendar for 2019

2018

October 31, 2018

Lending of bond funds of €2.5M with Vatel Direct (French version)
October 23, 2018

EUROBIO SCIENTIFIC certified ISO 13485 V2016
October 17, 2018

Eurobio Scientific and BIOGROUP-LCD enter into an agreement for the supply and maintenance of Multiplex Molecular Biology automated platforms
October 09, 2018

Eurobio Scientific - 2018 mid-year results
July 23, 2018

Consolidated turnover for the fist semester of 2018 increases by 29%
July 16, 2018

Eurobio Scientific acquires Dendritics, a company specializing in antibody development and manufacture
June 25, 2018

Eurobio Scientific will market the Quidel Triage range (PR in French)
June 21, 2018

Change of Eurobio scientific listing name and code by Euronext (PR in French)
June 14, 2018

Company name changed to Eurobio scientific, annual shareholders meeting (PR in French)
May 2, 2018

Renewal of the partnership with One Lambda in transplantation (PR in French)
April 23, 2018

DIAXONHIT – Group 2017 annual results (PR in French)

2017

October 30, 2017

DIAXONHIT – 2017 mid-year results (PR in French)
September 5, 2017

Diaxonhit acquires GENBIO in the US (PR in French)
April 27, 2017

DIAXONHIT – Group 2016 annual results (PR in French)
March 30, 2017

Acquisition of Eurobio is completed : Diaxonhit becomes a new European reference player in Diagnostics (PR in French)

2016

September 21, 2016

DIAXONHIT – 2016 mid-year results (PR in French)
May 25, 2016

DIAXONHIT and the University Hospitals of Strasbourg launch the Central European Laboratory dedicated to AlloMap® testing
March 24, 2016

DIAXONHIT - Group 2015 annual results
January 26, 2016

2015 Consolidated Income: €29.5 M 4% growth of in vitro diagnostic product sales

2015

September 24, 2015

DIAXONHIT – 2015 mid-year results
July 30, 2015

DIAXONHIT – HIV tests
June 3, 2015

DIAXONHIT - AlloMap® Heart Transplant Surveillance Solution
May 19, 2015

Diaxonhit and Felicitex Therapeutics, Inc. Announce Global Exclusive License of a Series of Lead-stage Anti-cancer Compounds from Diaxonhit for the Development of Therapeutics against Quiescent Cancer Cells
March 26, 2015

DIAXONHIT - Group 2014 annual results
January 26, 2015

DIAXONHIT – 2014 Consolidated Income
January 14, 2015

DIAXONHIT announces the CE marking of the BJI InoPlex® test and its commercial launch
January 12, 2015

DIAXONHIT announces that Strasbourg University Hospital will become its European Central Laboratory for processing the CareDx® AlloMap® heart transplant tests

2014

November 27, 2014

DIAXONHIT – Prosthetic joint infections test
November 18, 2014

DIAXONHIT – Thyroid cancer test
November 12, 2014

Renewal of commercial partnership with One Lambda, Inc. for diagnostic tests in transplantation
September 24, 2014

Completion of patients enrollment in the final validation study of the first diagnostic test for prosthetic bone and joint infections
September 18, 2014

DIAXONHIT Group 2014 half-year results
July 21, 2014

Diaxonhit in vitro specialty diagnostic sales further increase by 7% at mid-year
July 1, 2014

CareDx Announces the First Commercial European AlloMap Test Reported from its Reference Lab
May 5, 2014

Diaxonhit and CareDx Present New AlloMap® Clinical Abstracts at the Annual ISHLT Conference in San Diego
April 28, 2014

Diaxonhit receives financing from Bpifrance for the development of a
companion diagnostic for a therapeutic vaccine against AIDS
March 26, 2014

Diaxonhit reports 2013 results 2013 successful transformation into
a specialty in vitro diagnostics company
January 28, 2014

2013 consolidated income increases to €30.5 million 11% growth of in vitro diagnostic product sales
January 13, 2014

Diaxonhit enters into a distribution agreement with SAMSUNG " Health Medical Equipment " division for commercialization of point of care diagnostic tests

2013

October 16, 2013

Diaxonhit enters into exclusive partnership agreement with
Japanese Tosoh Group for marketing immunoassay instruments
25 septembre 2013

Diaxonhit strengthens its offering in the field of quality control for clinical laboratories
September 17, 2013

Half-year 2013 results Successful transformation of Diaxonhit, validated by the strong growth in revenues
September 3, 2013

Diaxonhit signs a research service agreement with Boehringer Ingelheim for the discovery of novel epitope targets in oncology
July 25, 2013

Diaxonhit mid-year revenues increase to €15,9 million
June 27, 2013

Diaxonhit Agrees to Commercialize in Europe the XDx AlloMap® Heart Transplant Test Following the Completion of Exclusive License Agreement
June 4, 2013

Diaxonhit and XDx Enter Into a Memorandum of Agreement for the Exclusive License to Market and Perform AlloMap® in Europe
April 23, 2013

Diaxonhit wins a major public tender from the Paris Hospitals (Assistance Publique – Hôpitaux de Paris)
March 26, 2013

Diaxonhit reports 2012 results
February 28, 2013

Diaxonhit solidifies its position as a major player in the field of transplantation
February 6, 2013

Diaxonhit is informed by Allergan that Bristol-Myers Squibb has decided to stop development of EHT/AGN 0001

Exonhit History

> 2012
> 2011
> 2010
> 2009
> 2008
> 2007
> 2006

InGen BioSciences

InGen BioSciences Press Releases History

2012

November 06, 2012

Exonhit announces the upcoming acquisition of InGen BioSciences, the leading independent distributor of in-vitro diagnostics in the French market
September 11, 2012

Exonhit – Half-year 2012 results
July 16, 2012

Alzheimer's disease: patient enrollment completed ahead of plan in Exonhit’s studies on AclarusDx®
June 5, 2012

EXONHIT RECEIVES € 1.93 MILLION FROM OSEO WITHIN THE PERSONALIZED MEDICINE TEDAC PROJECT IN CANCER
March 22, 2012

EXONHIT SA reports 2011 results
March 5, 2012

Exonhit is beneficiary of a grant from the European Union within the responsify consortium

2011

December 12, 2011

AclarusDx® : launch of observational study in France
November 2, 2011

Exonhit extends strategic collaboration with Allergan
October 26, 2011

Approval of US pilot clinical trial to evaluate AclarusDx™, the Exonhit investigational test for Alzheimer’s Disease diagnosis
October 10, 2011

Exonhit enters into Research Agreement with Pfizer to identify Alzheimer’s disease biomarkers
September 13, 2011

Significant achievements reached for EHT/AGN 0001 with Allergan, AclarusDx®, and EHT Dx14
September 7, 2011

Isabelle Barber is appointed to Exonhit Management Board
July 25, 2011

Exonhit and BGI announce successful completion of a promising next-generation sequencing project
July 19, 2011

Exonhit announces successful completion of the second phase of EHT Dx14 clinical validation
June 29, 2011

Exonhit reports key progress in the introduction of AclarusDx™ in the French IVD market
May 18, 2011

Exonhit’s extraordinary shareholders’ meeting
April 27, 2011

ExonHit’s combined ordinary and extraordinary annual shareholders’ meeting
April 4, 2011

ExonHit announces publication of EHT 0202 Phase IIa results in Current Alzheimer Research
March 29, 2011

ExonHit announces successful completion of the first phase of EHT Dx14 ongoing clinical validation.
March 15, 2011

ExonHit announces CE marking of AclarusDx™
March 15, 2011_2

ExonHit Therapeutics reports 2010 results

2010

December 20, 2010

ExonHit Therapeutics awarded two discovery grants by the US Federal Government
November 8, 2010

ExonHit presents promising data on genomic biomarkers in Alzheimer’s disease clinical trials
October 25, 2010

ExonHit announces termination of agreement to acquire RedPath
September 21, 2010

ExonHit announces Highmark’s decision to maintain coverage of PathFinderTG® - Pancreatic cancer test
September 16, 2010

ExonHit Therapeutics – Strong growth of half-year 2010 results
september 6, 2010

ExonHit will participate to the Paris Midcap Event on September 20 & 21
July 9, 2010

ExonHit’s extraordinary shareholders’ meeting on
second notice
June 30, 2010

ExonHit’s extraordinary shareholders’ meeting
June 23, 2010

ExonHit updates its shareholders regarding the extraordinary shareholders’ meeting about RedPath acquisition
June 18, 2010

ExonHit updates its shareholders on the acquisition of RedPath Integrated Pathology
June 14, 2010

ExonHit signs an exclusive agreement with Genmab for novel splice variant targets in breast cancer
June 9, 2010

ExonHit discloses the final terms of the acquisition of RedPath Integrated Pathology
May 26, 2010

ExonHit announces the holding of an extraordinary shareholders’ meeting to approve the acquisition of RedPath Integrated Pathology
May 19, 2010

Change in ExonHit Management Board
May 10, 2010

ExonHit’s 2010 combined ordinary and extraordinary shareholders’ meeting
April 28, 2010

ExonHit’s 2010 combined ordinary and extraordinary shareholders’ meeting
April 26, 2010

ExonHit to acquire RedPath Integrated Pathology, Inc. and accelerate growth in molecular diagnostics
April 20, 2010

ExonHit confirms its intention to complete an external growth transaction in 2010
April 06, 2010

ExonHit receives "Innovative Company" accreditation from the French state innovation agency OSEO
March 31, 2010

ExonHit will participate to the Paris Smallcap Event on April 12 & 13
March 29, 2010

ExonHit presents new data on its Alzheimer’s lead candidate at the International Geneva/Springfield Symposium
March 10, 2010

ExonHit Therapeutics reports 2009 annual results
March 8, 2010

ExonHit and bioMérieux decide not to pursue colon cancer program
March 3, 2010

ExonHit reports out-licensing of EHT/AGN 0001 by Allergan to Bristol-Myers Squibb
February 23, 2010

ExonHit announces the inclusion of proprietary lead compounds into Allergan collaboration
February 11, 2010

ExonHit chosen to join the European Innovative Medicines Initiative consortium on Alzheimer’s disease

2009

December 16, 2009

ExonHit announces the success of its capital increase
December 3, 2009

ExonHit launches first product in Alzheimer
November 5, 2009

ExonHit Therapeutics announces the appointment of its new Chief Financial Officer
November 2, 2009

ExonHit will participate in the MAPT study for the prevention of cognitive decline in old people
October 30, 2009

ExonHit presents new clinical advances on its Alzheimer’s diagnostic and therapeutic programs
October 26, 2009

ExonHit strengthens its intellectual property position in the US
September 14, 2009

ExonHit presents promising first patient results for EHT 0202, its Alzheimer’s candidate drug
September 8, 2009

ExonHit will participate to the Paris Midcap Event on September 21 & 22
July 30, 2009

ExonHit Therapeutics – First half 2009 results
July 8, 2009

ExonHit raises EUR 1.45 million through the exercise of warrants
June 26, 2009

ExonHit announces the departure of its Chief Financial Officer
June 16, 2009

ExonHit announces last patient out for EHT 0202 Phase IIa study in Alzheimer
May 27, 2009

ExonHit and Institut Gustave Roussy announce the signing of a license agreement for novel breast cancer diagnostic assay.
May 19, 2009

ExonHit enters into a liquidity agreement.
May 6, 2009

ExonHit’s 2009 Extraordinary Annual Meeting.
April 28, 2009

ExonHit’s 2009 Ordinary Annual Meeting.
April 16, 2009

ExonHit will participate to the paris Smallcap event.
March 31, 2009

ExonHit expands neurological research activities to epilepsy.
March 16, 2009

ExonHit reports proof of concept in breast cancer diagnostic using its SpliceArray^TM platform.
March 9, 2009

ExonHit Therapeutics shareholders equity strengthened by exercice of more than half of its convertible bonds.
March 4, 2009

ExonHit Terapeutics invested strongly in 2008 for pivotal 2009 results.
February 26, 2009

ExonHit Therapeutics reports advancements in the clinical development of EHT 0202, its phase II drug for Alzheimer's disease.
January 6,2009

ExonHit therapeutics expands strategic collaboration with allergan.

2008

December 23,2008

ExonHit Therapeutics allocates free subscription warrants to all shareholders.
December 3,2008

ExonHit is honoured by the innovation trophy from the nationnal institute of industrial property.
November 27,2008

ExonHit launches mouse genome SpliceArray^TM for use in human disease modeling studies.
October 29,2008

ExonHit announces new scientific publications on the use of SpliceArrayT.
September 22,2008

ExonHit exclusive partnership with Xentech to provide molecular profiling services.
July 29,2008

ExonHit Therapeutics achievements for first half.
July 2,2008

ExonHit presents therapeutic and diagnostic programs for Alzheimer at ICAD.
June 4,2008

Loic Maurel joins ExonHit therapeutics to become CEO.
May 6,2008

ExonHit therapeutics launches the rat genome SpliceArrayT products.
April 30, 2008

Appointment of Frederic Desdouits on the supervisory board of ExonHit Therapeutics.
March 31,2008

ExonHit appoints a new Management Board.
March 25,2008

Exonhits EHT 0202 counters scopolamines detrimental.
March 5,2008

ExonHit therapeutics financial results 2007.
January 16,2008

ExonHit builds a new organization.
January 9,2008

ExonHit and bioMerieux amend their strategic partnership.

2007

December 20, 2007

ExonHit initiates a Phase 2 clinical trial for EHT 0202 in Alzheimer's disease
November 8, 2007

ExonHit completes a prototype to detect Alzheimer's disease from blood
August 28, 2007

ExonHit strikes a milestone in its collaboration with Allergan
July 31, 2007

ExonHit Therapeutics - Achievements for first half 2007
June 7, 2007

In 2009 ExonHit aims to ask for market clearance in Europe for a blood diagnostic test for Alzheimer's disease
June 1st, 2007

ExonHit issues 400 000 new shares through the use of PACEO
May 11, 2007

Deborah Smeltzer appointed member of the supervisory board of ExonHit Therapeutics
April 17, 2007

ExonHit Therapeutics and bioMérieux present additional results in their breast cancer blood biomarkers program
March 15, 2007

ExonHit identifies a panel of genes to diagnose, from a blood, Alzheimer's disease
March 6, 2007

ExonHit 2006 financial results
February 26, 2007

ExonHit issues 400 000 new shares through the use of PACEO
February 20, 2007

ExonHit launches Human Genome SpliceArray^TM
January 25, 2007

ExonHit raises 3.2 million euros through the exercise of warrants
January 4, 2007

ExonHit Therapeutics and bioMerieux initiate a third diagnostic programme

2006

November 23, 2006

ExonHit Therapeutics - Clinical Therapeutic Programs
November 8, 2006

Appointment of a new member of the Supervisory Board
October 25, 2006

ExonHit success of the issuance of convertible bonds
October 24, 2006

ExonHit presents preliminary characteristics of the issuance of convertible bonds
October 19, 2006

ExonHit to start a research program on a blood diagnostic for Atherosclerosis
September 20, 2006

ExonHit Therapeutics - solid first half 2006
September 19, 2006

ExonHit extends strategic alliance with Allergan
September 12, 2006

ExonHit appoints John Jaskowiak as Executive Business and marketing
September 12, 2006

ExonHit - internet portal to market its microarrays
September 7, 2006

ExonHit licences Merck rights to RNA splicing microarray patent
September, 7 2006

ExonHit produces a new map for human genome expression
July 25, 2006

First half 2006 revenues up by 46%
july 5, 2006

ExonHit - Financial press release calendar
June 7, 2006

ExonHit - Emission of free warrants
June 16, 2006

ExonHit - Success of the secondary offering
June 14, 2006

Changes in the secondary offering
June 7, 2006

ExonHit - Secondary offering and free allocation of BSA
May 31, 2006

Agilent and ExonHit expand agreement
May 16, 2006

Alzheimer disease diagnostic patent
April 18, 2006

SpliceArrays on Affymetrix GeneChip platform
April 5, 2006

ExonHit annonces the partial release of the lock-up for its principal shareholders
March 29, 2006

ExonHit bioMérieux breast cancer
February 21, 2006

2005 Financial Results
February 17, 2006

ExonHit therapeutics will begin continuous trading on Alternext on March 6, 2006
February 9, 2006

ExonHit’ SpliceArray service welcomes its 50th commercial project
January 5, 2006

ExonHit therapeutics strengthens its balance sheet